Business Overview

Echo Therapeutics, Inc. (NASDAQ: ECTE) is a transdermal medical device company with deep expertise in advanced skin permeation technology. Echo is developing its Prelude^® SkinPrep System as a platform technology to allow for significantly enhanced skin permeation that will enable both needle-free drug delivery and analyte extraction. Utilizing the patented, core skin permeation technology found in Prelude, Echo is developing its needle-free Symphony^® tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system for use in hospital critical care units and for people with diabetes.

Echo currently has two key strategic partnerships in place:

• Echo has granted Ferndale Pharma Group, Inc. and its wholly owned subsidiary Eloquest Healthcare Inc. a license to develop, market and sell the Prelude device for enhanced, fast acting and needle-free delivery of Ferndale's topical lidocaine product in North America and the U.K.
• Echo has granted Handok Pharmaceuticals Co., Ltd. a license to develop, market and sell the Symphony^® tCGM System for continuous glucose monitoring in South Korea.